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Abstract
Since its introduction as a public health programme in the United
States in the early 1960s, newborn blood screening (NBS) has evolved
from the detection of phenylalanine levels on filter paper to the appli-
cation of DNA-based technologies to identify T-cell lymphopenia in
infants with severe combined immunodeficiency. This latter use of
NBS has required the development of an assay for T-cell lymphopenia
based on the quantification of T-cell receptor excision circles (TRECs)
that could be performed on dried blood spots routinely collected from
newborn infants. The TREC-based NBS was developed six years ago,
and there have already been 7 successful pilot studies since then.
Similarly, efforts are now being made to establish a screen for B-cell
defects, in particular agammaglobulinaemia, taking advantage of the
introduction of the method for the quantification of K-deleting recom-
bination excision circles (KRECs). A further achievement of NBS
could be the simultaneous recognition of T- and B-cell defects using
the combined quantification of TRECs and KRECs from Guthrie card
blood spots. This approach may help the early identification of infants
with T- and B-cell deficiencies so that they can then be referred to spe-
cialised paediatric centres, where a precise diagnosis of severe com-
bined immunodeficiency and agammaglobulinaemia can be per-
formed, and where then they can immediately receive specific therapy.
Simultaneous TREC and KREC quantification should also allow classi-
fication of patients into subgroups and help identify children with less
serious primary immunodeficiencies. This would help avoid the oppor-
tunistic infections and frequent hospitalisations that result from a late
or lack of diagnosis.
Newborn screenings
The goal of newborn blood screening (NBS) is to identify pre-symp-
tomatic newborns with potentially serious or fatal disorders which
could be successfully treated, leading to significant reductions in mor-
bidity and mortality. NBS debuted as a public health programme in the
US in the early 1960s, and has expanded to countries around the world,
with different testing options in each country. NBS has progressively
evolved since 1963, when Guthrie and Susi demonstrated that postna-
tal testing of dried blood spots on filter paper led to the identification
and treatment of infants prior to the development of the cognitive
deficits associated with phenylketonuria.1 The application of tandem
mass spectrometry also allowed simultaneous screening for multiple
disorders.2 More recently, the advent of DNA-based technologies has
again shifted the paradigm of NBS, offering the potential of screening
for numerous disorders at the same time. Therefore, the number of
NBS-analysed disorders has progressively grown. 
The American College of Medical Genetics recommends a uniform
panel of 29 disorders that all infants born in every state should be
screened for.3 Therefore, every year, millions of babies in the US are
routinely screened for congenital deafness and, using a few drops of
blood from the newborn’s heel, for blood cell disorders (sickle cell
anaemia, sickle cell disease, and Hb S/beta-thalassaemia), inborn
errors of amino acid metabolism (tyrosinaemia I, argininosuccinic
aciduria, citrullinaemia, phenylketonuria, maple syrup urine disease,
and homocystinuria), inborn errors of organic acid metabolism (glu-
taric acidaemia type I, hydroxymethylglutaryl lyase deficiency, isova-
leric acidaemia, 3-methylcrotonyl-CoA carboxylase deficiency, methyl-
malonyl-CoA mutase deficiency, methylmalonic aciduria, cblA and cblB
forms, beta-ketothiolase deficiency, propionic acidaemia, and multi-
ple-CoA carboxylase deficiency), inborn errors of fatty acid metabolism
(long-chain hydroxyacyl-CoA dehydrogenase deficiency, medium-
chain acyl-CoA dehydrogenase deficiency, very-long-chain acyl-CoA
dehydrogenase deficiency, trifunctional protein deficiency, and carni-
tine uptake defect) and miscellaneous multisystemic diseases (cystic
fibrosis, congenital hypothyroidism, biotinidase deficiency, congenital
adrenal hyperplasia, and classical galactosaemia).3 In addition,
expanded screening programmes have been developed in different
states in the US, with some programmes covering almost 50 condi-
tions.4 In Europe, several countries have expanded their NBS pro-
grammes. Some programmes screen for only one or two conditions,
Significance for public health
Primary immunodeficiencies include a group of more than 200 different dis-
eases. Since the clinical severity ranges from mild to potentially life-threat-
ening, major efforts are currently being made to develop methods to detect
patients with these diseases in the neonatal period. Early identification is
highly desirable. In fact, making a diagnosis before vaccines or blood prod-
ucts are administered, as well as before the infection develops, allows the
patient to proceed to haematopoietic stem cell transplantation, and receive
enzyme replacement and gene therapies. Indeed, the best outcome for the
most severe form of primary immunodeficiency, as with many other condi-
tions for which newborn screenings are now performed, is achieved when
treatment is given in the first months of life, ideally before clinical presen-
tation. The pilot studies of newborn screenings for severe combined immun-
odeficiency have demonstrated their cost-effectiveness and have also proved
successful in terms of public health resulting from improved Quality of Life
and survival of children with these diseases.
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whereas others screen for up to a few dozen. For example, the UK and
France National Screening Committees recommend that all babies in
their countries should be screened for phenylketonuria, congenital
hypothyroidism, sickle cell disease, and cystic fibrosis, with the addi-
tion of medium-chain acyl-CoA dehydrogenase deficiency in the UK
and congenital adrenal hyperplasia in France.5 In Italy, the application
of the NBS programme application differs widely between regions. In
some regions, only the three tests listed in the national programme are
performed while other regions screen for up to 47 rare metabolic dis-
eases. While developing countries face additional challenges related to
poor economies, unstable governments, unique local cultures, geo-
graphical extremes, and different public health priorities,6-9 all other
countries face challenges in implementing NBS because of the identi-
fication of the causes of genetic disorders, advances in detection tech-
nologies, and the development of better treatment regimens. One of the
last NBS tests to be introduced measures the presence of T-cell defi-
ciencies using T-cell receptor excision circle (TREC) quantification.
Primary immunodeficiencies 
Primary immunodeficiencies (PID) are rare inherited disorders of
the immune system. They are genetically determined and may occur
alone or as part of a syndrome. Several types of PID have been
described by Al-Herz et al.10 and the heterogeneity within each disorder
may be considerable. They typically manifest during infancy and child-
hood as abnormally frequent/recurrent or unusual infections, often
accompanied by immunoregulatory defects.11 The vast majority of
patients with PID have decreased T- and/or B-cell functions that gross-
ly impair immunity. B-cell defects lead to antibody deficiencies. As a
result of a mutation in the BTK gene, a subgroup of these patients have
X-linked agammaglobulinaemia (XLA) due to a B-cell differentiation
arrest in the bone marrow and the consequent absence of mature B
cells and serum immunoglobulins (Ig).12 More than 30% of these
patients develop irreversible organ damage in childhood or early adult-
hood, mainly in the lungs.12,13 Non-XLA is characterised by hypo-gam-
maglobulinaemia with decreased B-cell counts (less than 2% mature B
cells) in the absence of the BTK gene mutation.14 In patients with XLA
and non-XLA, recurrent infections appear between three and 18
months of age, whereas the mean age at diagnosis is three years.15
This delayed diagnosis results in frequent hospitalisations because of
pneumonia, sepsis, meningitis, and other bacterial infections, which
frequently require the intravenous administration of antibiotics and
can be fatal. Thus, early diagnosis and treatment, including periodic
intravenous Ig replacement therapy, are essential to improve the prog-
nosis and Quality of Life of these patients. 
T-cell defects result in combined immunodeficiencies, affecting both
cellular and humoral immunity, with severe combined immunodefi-
ciency (SCID) being the most serious and lethal form. SCID, which was
reported for the first time more than 60 years ago,16 comprises a het-
erogeneous group of diseases, characterised by profound deficiencies
of T- and B-cell functions, and, in some types, also of natural killer (NK)
cells.17,18 The overall frequency of SCID is estimated to be between
1:50,000 and 1:100,000 live births.18 These infants develop failure to
thrive, chronic diarrhoea, and infections in the first months of life.
Infections can occur with common pathogens, but most of the time the
infants also suffer from opportunistic infections, such as thrush or
Pneumocystis jiroveci pneumonia. Graft-versus-host disease caused by
maternal T-cell engraftment may occur in these patients, who also
show skin rashes and organomegaly.
SCID is now known to be caused in humans by mutations in several
different genes, such as cytokine receptor genes, antigen receptor
genes and others,19 but there are many other probable causes yet to be
discovered. An updated classification of SCID is based on the underly-
ing genetics and prevalent molecular pathogenetic mechanisms and
includes the following:20 impaired cytokine-mediated signalling, alter-
ations in V(D)J recombination, impaired signalling through the pre-T
cell receptor (TCR), increased lymphocyte apoptosis, absence of the
thymus, alterations in thymus embryogenesis, impaired calcium flux,
and other mechanisms. SCID infants, regardless of the disease geno-
type, show distinct lymphocyte phenotypes. They all have a profound T-
cell deficiency, and those T cells that are present are usually of mater-
nal origin, having crossed the placenta. B cells can be elevated, normal
or absent, depending on the type of SCID, and the NK-cell number is
variable. Therefore, according to the presence or absence of the T, B
and NK lymphocytes, SCID can also be phenotypically categorised as
the T−B−NK−, T−B+NK−, T−B−NK+, and T−B+NK+ (with minus meaning
absence or severely reduced counts) subtypes. For example, T−B+NK-
SCID, accounting for up to 50% of SCID cases, is predominantly X-
linked, and is caused by mutations in the IL2RG gene encoding the
interleukin 2 receptor gamma chain. Although less frequent, JAK3 defi-
ciency produces a similar T−B+NK- lymphocyte phenotype. 
The early recognition of SCID should be considered a paediatric
emergency because a diagnosis before live vaccines or prior to the
development of infections permits lifesaving unfractionated HLA-iden-
tical or T-cell depleted haploidentical non-ablative haematopoietic stem
cell transplantation, enzyme replacement therapy, or gene therapy.21-29
However, these infants often appear normal at birth and have no fami-
ly history of immunodeficiency,30 and consequently, many of them are
not identified until a life-threatening infection occurs. This is impor-
tant because the long-term prognosis of infants with SCID and other
serious immunodeficiencies can be markedly improved if the diagnosis
is made early, before the onset of severe infections.31 Indeed, if SCID is
not detected until the infant is older, there is a much higher likelihood
of death from live vaccines, graft-versus-host disease from non-irradi-
ated blood products, or infections, before a successful definitive thera-
py can be adopted.21,23,24
Pilot studies for newborn blood screening forsevere combined immunodeficiency using T-cellreceptor excision circles quantification
Because SCID is not apparent at birth and early recognition is essen-
tial for life-saving treatment, it has, for many years now, been recog-
nised as a candidate for NBS.32-35 Indeed, the disease satisfies the cri-
teria that the Secretary’s Advisory Committee on Heritable Disorders in
Newborns and Children recommends for routine inclusion in NBS.
These criteria are that: i) the frequency of the disease in the popula-
tion is high enough to warrant screening; ii) the untreated natural his-
tory of the disease is well-defined; iii) the untreated disease clearly
confers significant morbidity and/or mortality; iv) the disease is treat-
able, and treatment significantly improves outcome; v) disease testing
is safe, simple, and sufficiently sensitive to detect all cases; vi) specif-
ic confirmatory testing is available for the disease; and vii) the test,
treatment, and treatment outcomes are cost-effective with respect to
the non-treatment of the disease.36
An initial screening test for SCID was based on the detection of
peripheral blood lymphopenia. However, a complete blood count cannot
be performed using filter paper-dried blood spots, making this test
unsuitable for NBS. In addition, the quantification of peripheral blood
lymphocytes may fail to identify some infants with SCID due to the
presence of normal B-cell or NK-cell numbers, the maternal engraft-
Reviews and Meta-Analysis
No
n-c
o
me
rci
al 
us
e o
nly
ment of T cells, and/or the expansion of a few T-cell clonotypes.37,38
Therefore, no laboratory test on newborn dried blood spots was avail-
able to detect T-cell lymphopenia in infants with SCID until 2005 when
real-time polymerase chain reaction (PCR) for the quantification of
TRECs was developed and validated for population-based screening.39
TRECs are created during the process of lymphocyte differentiation
(Figure 1A) when TCR rearrangements occur within the thymus. The
rearrangement of the TCR alpha (TCRA) chain has the peculiarity of
involving the excision of delta-coding segments, which encode the
delta chain of gamma/delta T cells that, being nestled in the TCRA locus
between the variable (V) and junctional (J) gene segments, must be
excised to generate the TCRA chain. The excised circularised DNA ele-
ments are called TRECs (Figure 1B). 
Approximately 70% of T cells generate a TREC.40 Several properties
were established for TRECs that make them useful markers of thymic
output: they are stable, do not degrade easily over time, are not repli-
cated when a cell divides, and are (almost) exclusively of thymic origin,
without extrathymic sources of TCR rearrangements.41,42
After the demonstration that the TREC assay detects SCID patients
regardless of the genetic cause,43 the test was modified and refined so it
could be performed using blood from dried spots, was highly sensitive
and specific for SCID, and was cost-effective and reproducible, thereby
becoming amenable to high-throughput population-based testing.44 At
that point, pilot studies of NBS for SCID, integrated with plans for its
definitive diagnosis and management, were established in some US
states.30 In 2008, Wisconsin became the first state to implement manda-
tory NBS for T-cell deficiency,45 followed by Massachusetts in February
2009,46,47 and later by New York, the Navajo Nation, California, Puerto
Rico and Louisiana.29 With the exception of California, where a TREC
assay kit under development by a medical technology company is being
used, all the other states are using in-house modifications of the TREC
assay.39,44,46,47 By April 30th 2011, these pilot studies had been performed
on 961,925 newborns, and had identified 14 cases of SCID, 6 cases of
SCID variants and 40 cases of T-cell lymphopenia that were not related to
SCID.29 All infants diagnosed with SCID in Wisconsin and Massachusetts
have undergone transplantation or enzyme replacement therapy and no
deaths have been reported.45,48
Identification of patients with agammaglobuli-naemia using K-deleting recombination excision circle quantification
Taking advantage of the introduction of the K-deleting recombina-
tion excision circle (KREC) method to study the replication history of
B cells,49 efforts have recently been made to establish a NBS for B-cell
[Journal of Public Health Research 2013; 2:e3] [page 11]
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Figure 1. T-cell differentiation and T-cell receptor excision circle formation. (A) Lymphoid progenitors, which have developed from
haematopoietic stem cells in the bone marrow, migrate to the thymus to complete their antigen-independent maturation into func-
tional T cells. In the thymus, the T cells develop their specific T-cell markers and undergo thymic education through positive and neg-
ative selection. (B) Because TCRD gene segments are interspersed within TCRA gene segments along chromosome 14q11 (TCRAD
locus), following V(D)J recombination of the TCRD locus, the entire locus is preferentially deleted by δREC–ψJα rearrangements. This
process gives rise to a δREC–ψJα signal joint on an excision circle (TREC) and a δREC–ψJα coding joint in the genome. 
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maturation defects.14 During the process of B-cell maturation, KRECs
are produced by recombination events that determine the allelic and
isotypic exclusion of the Kappa chain.50 Indeed, during B-cell develop-
ment, KRECs are produced in those B lymphocytes that, after the Ig
heavy chain rearrangement, have failed to productively rearrange the
Ig light Kappa chain genes (IGK) on one or both alleles.51 In these cells,
the IGK locus becomes non-functional through the deletion of the con-
stant K-gene segment (IGKC) by recombination of the K-deleting ele-
ment (Kde), which is a sequence located approximately 24 kb down-
stream of the constant K-gene segment, with one of the two upstream
recombination signal sequences.51 When the Kde recombines with the
recombination signal sequence located in the intron between the junc-
tion and constant K-gene segments, portions of the DNA are deleted,
and the ligation of the excised recombination-signal ends generates
the circularised DNA elements defined as KRECs (Figure 2A). These
products persist in the cell, are unable to replicate, and are diluted as a
result of cell division.
The frequency of these recombination events in human B-cell malig-
nancies ranged from 31% to 69%; approximately 50% of transformed B
cells should contain KRECs.52 Therefore, the quantification of KRECs
was initially used to determine the number of developing B lympho-
cytes in the bone marrow of children with B-precursor acute lym-
phoblastic leukaemia treated with allogeneic human stem cell trans-
plantation.53 However, as IGK gene deletion occurs physiologically in all
B lymphocytes that fail to productively rearrange the IGK genes on one
or both alleles, the number of KRECs has been be proposed to be a
quantitative marker of bone marrow output in all individuals.54
Furthermore, because KRECs are not supposed to be produced in XLA
and non-XLA patients because their B-cell maturation defects occur
before K-deleting recombination occurs (Figure 2B), the KREC meas-
urement can potentially be applied to identify these types of B-cell defi-
ciencies, which account for approximately 20% of all B-cell defects. In
addition, some other types of combined immunodeficiencies show an
arrest at the B-cell maturation stage and can also be identified using
KREC detection.
Indeed, more than 200 KREC copies/μg DNA were present in the
dried blood spots of healthy children, whereas no KRECs were detected
in 30 XLA and 5 non-XLA patients.12,14 This suggests that the measure-
ment of KRECs in neonatal dried blood spots could be used in an NBS
that identifies neonates with early B-cell maturation defects. This early
Reviews and Meta-Analysis
Figure 2. B-cell differentiation and K-deleting recombination excision circle formation. (A) B-cell development begins as lymphoid stem
cells differentiate into progenitor B cells (pro-B cells), which are the earliest distinctive B-lineage cells. During the antigen-independ-
ent maturation phase, immune competent B cells expressing membrane IgM and IgD are generated in the bone marrow. Only approx-
imately 10% of the potential B cells reach maturity and leave the bone marrow. Naïve B cells in the periphery die within a few days
unless they encounter soluble protein antigen and activated Th cells. Once activated, B cells proliferate within secondary lymphoid
organs. (B) B-cell differentiation from the stem-cell to the plasma-cell stages is characterised by Ig V(D)J rearrangement, somatic muta-
tion and Ig class switching. The V(D)J recombination on the IGK locus results in a Vκ-Jκ coding joint. Subsequent rearrangement
between the intronRSS and the Kde element can render the IGK allele non-functional by deleting the IGKC exon and the enhancers.
Consequently, the coding joint precludes any further rearrangements in the IGK locus and, therefore, remains present in the genome,
whereas an intronRSS-Kde signal joint is formed on the KREC.
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identification of children at risk should improve their future Quality of
Life and help reduce health care costs, considering that the clinical
phenotype of agammaglobulinaemia is milder than that of SCID.
Therefore, the disease would be underdiagnosed in the first years of
life in the absence of a screening programme, with patients developing
serious organ damage before an accurate diagnosis could be made.
Simultaneous quantification of T- and B-celldefects using the T-cell receptor excision cir-cles/K-deleting recombination excision circlesassay
In 2010, we improved the methods for TREC and KREC quantifica-
tion by developing a duplex quantitative real-time PCR protocol that
allows an accurate and simultaneous assessment of both targets.54 For
their absolute quantification, a standard curve is created using serial
dilutions of TREC and KREC signal joint constructs cloned in a bacter-
ial plasmid, together with a control gene, the TCRA constant gene
(TCRAC). The primers and probes used for the duplex real-time PCR
assay are listed in Table 1. 
The main advantage of the combined TREC/KREC assay is that the
variability related to DNA quantification is eliminated by the use of the
triple-insert plasmid in which the TREC, KREC and TCRAC gene frag-
ments are present in a 1:1:1 ratio. This allows a more accurate assess-
ment of the TREC and KREC copy number. Furthermore, the simultane-
ous quantification of the two targets in the same reaction contains the
reagent costs. The number of TRECs or KRECs per 106 peripheral blood
mononuclear cells (PBMCs) is calculated by dividing the mean quanti-
ty of TRECs or KRECs by the mean number of TCRAC gene copies,
which has to be divided by 2 because there are two TCRAC gene copies
in each cell (i.e. one for each chromosome) and then multiplied by 106.
This value, together with the lymphocyte plus monocyte count (which
are the cells obtained in the PBMC preparation) in 1 mL of blood, was
used to calculate the number of TRECs or KRECs per mL of blood as fol-
lows:
TRECs or KRECs/mL = (TRECs or KRECs per 106 PBMCs) x (lympho-
cyte + monocyte count in 1 mL of blood)/106.54
Using this strategy, we found that in healthy subjects, the number of
TRECs and KRECs is correlated to age (Figure 3) and that, in particu-
lar, it significantly decreases over time, with a steeper slope in the first
three years of life.55 With this assay, we demonstrated that the T- and
B-cell reconstitution in children with different PIDs who underwent
human stem cell transplantation or were cured with enzyme replace-
ment therapy using pegylated bovine adenosine deaminase involves
the mobilisation of both T and B cells from the respective production
and maturation sites, and that the increase in TRECs and KRECs can
be either strictly associated with or independent from one another.54,56
These results demonstrated that knowledge of the numbers of TRECs
and KRECs, obtained with an assay that can be easily introduced into
routine laboratory practice, is highly informative and can be used for a
more precise identification of patients with PID or for their therapeu-
tic monitoring. Accordingly, this method has been recently validated in
a cohort of 2560 anonymised NBS cards and in 49 originally stored
Guthrie cards from patients diagnosed with different PIDs, allowing the
identification of patients with SCID, XLA, ataxia-telangiectasia (AT)
and Nijmegen-breakage syndrome.57 Therefore, the set up of a single
assay for the simultaneous quantification of TRECs and KRECs will
permit NBS for both SCID and agammaglobulinaemia, which together
have a combined estimated incidence of 1:30,000-1:50,000 births.
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Figure 3. Age-dependence of T-cell receptor excision circles and K-deleting recombination excision circles. The numbers of T-cell recep-
tor excision circles (TRECs) and K-deleting recombination excision circles (KRECs) in healthy individuals. The graphics were prepared
using data from Sottini et al.54 and Serana et al.55,56
Table 1. Primer and probe sequences for TREC and KREC quantifica-
tion.
Primer* Sequence
SJ TRECs forward 5’-CAC ATC CCT TTC AAC CAT GCT-3’
SJ TRECs reverse 5’-TGC AGG TGC CTA TGC ATC A-3’
SJ KRECs forward 5’-TCC CTT AGT GGC ATT ATT TGT ATC ACT-3’
SJ KRECs reverse 5’-AGG AGC CAG CTC TTA CCC TAG AGT-3’
TCRAC forward 5’-TGG CCT AAC CCT GAT CCT CTT-3’
TCRAC reverse 5’-GGA TTT AGA GTC TCT CAG CTG GTA CAC-3’
Probe* Sequence
TRECs probe 5’-FAM-ACA CCT CTG GTT TTT GTA AAG GTG CCC ACT-TAMRA-3’
KRECs probe 5’-HEX-TCT GCA CGG GCA GCA GGT TGG-TAMRA-3’
TCRAC probe 5’-FAM-TCC CAC AGA TAT CCA GAA CCC TGA CCC-TAMRA-3’
*Sottini et al.54
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Furthermore, this test allows the separation of T-cell deficient cases
into B-cell positive and B-cell negative subgroups, guiding additional
diagnostics toward either T−B+ or T−B− SCID.
Limitations of the introduction of newbornblood screening for primary immunodeficiencies
The use of the TREC assay has identified a large number of subjects
that do not meet the criteria for SCID. Some of these other conditions,
such as DiGeorge syndrome and Down syndrome, are known to result
in T-cell lymphopenia,45,58 whereas others were unexpected and many
remain undefined. In particular, premature babies have been shown to
have a lower number of TRECs than full-term babies, despite not being
immunodeficient.59 Moreover, the TREC and KREC assay may identify
other forms of immunodeficiency, some of them severe, for which a
definitive treatment is not available, e.g. AT.57,60 Therefore, it is impor-
tant to emphasise that the identification of SCID and agammaglobuli-
naemia at birth must be based on a two-tier assay, with TREC/KREC
determination only being the first tier. Appropriate second-tier assays
must be used to define the disease (if any) that results in the low
TREC/KREC values. For some disorders, such as AT, defining the dis-
ease at birth may indeed prove challenging because the values of alpha-
fetoprotein in newborns are elevated.61 This requirement of a two-
tiered system may represent an important limitation of the use of the
TREC/KREC assay for the population-based screening of genetic condi-
tions in newborns. Other principal obstacles to the full implementation
of NBS for PID could be the costs of setting up the screening test and
the possibility that the combined measurement of TRECs and KRECs
may generate higher call rates for newborns to be on clinical follow up,
which in turn has an impact on the total screening costs. However, the
introduction of the SCID NBS in the pilot studies had an approximate
cost of less than 1 million dollars,29 whereas in the US, the cost of treat-
ing one baby with SCID that is not diagnosed until he or she has a seri-
ous infection can easily exceed 2 million dollars. There is also a strik-
ing difference with regard to the costs for transplantation in SCID
infants under 3.5 months of age (approx. 1 million dollars) and the
costs for those aged over 3.5 months (more than 4 million dollars).29,62
An initial study, performed before the introduction of the TREC assay
on dried blood spots, demonstrated that a SCID screening test that cost
approximately 5 US Dollars would be considered cost-effective.63
However, the study incorporated limited information about the care
costs or outcome differences between infants identified before and
after becoming symptomatic. This limitation was bypassed by a recent
study that evaluated the cost-effectiveness of universal screening using
a model incorporating the impact of early detection on the natural his-
tory of SCID.62 The authors demonstrated that assuming a SCID inci-
dence of 1:75,000 births and test specificity and sensitivity of 0.99 each,
the screen remained cost-effective up to a maximum cost of 15 dollars
per infant screened.62 Therefore, considering that the TREC assay is
relatively inexpensive, with a cost of approximately  5.50 dollars per
assay,45 that the incidence of T-cell lymphopenia is relatively high, and
that better health outcomes and lower costs are associated with earlier
stem cell transplantation, NBS for SCID meets the reasonable stan-
dards of willingness-to-pay and could be a worthwhile addition to NBS
panels. Despite the favourable evaluation of SCID based upon the NBS
guidelines, national implementation is pending in most countries
which have long-lasting traditions of their own NBS programmes. The
inclusion of KREC detection in the test only slightly increases the cost
because it only involves the addition of a single reagent to the assay.
Thus, a single assay capable of screening for both SCID and agamma-
globulinaemia, which together have a combined estimated incidence of
1:30,000-1:50,000 births, should further improve the cost-effectiveness
of NBS. Additional preventive medical research for other severe PIDs,
including, but not limited to, inherited agammaglobulinaemias and
haemophagocytic syndromes,64 would be advisable.
The implications of NBS for PID in countries other than the US can-
not be easily established as the attributed value for a quality life-year
considerably differs among countries, particularly among the US,
Europe and other regions. Indeed, although PIDs are mentioned with-
in those disorders that might be considered for the gradual expansion
of NBS in the member states of the European Union,65 developing
countries will probably face additional challenges related to poor
economies, unstable governments, unique local cultures, geographical
extremes, and different public health priorities.
Conclusions
Newborn blood screening for SCID and other T-cell deficiencies,
based on TREC quantification, was the first screening introduced for
PID, but with the advent of modern molecular technologies, screening
for other immune system defects will probably be available soon.
One of the most promising candidates for NBS protocols is the com-
bined quantification of TRECs and KRECs that could support early diag-
nosis, classification of patient subgroups, and evaluation of stem cell
replacement therapy for both T- and B-cell defects.
In order to achieve this, clinicians have to play an active role in pro-
moting NBS for PID and other T- and B-lymphocyte abnormalities, and
work closely with public health officials and NBS committees. They also
have to offer their expertise to advise laboratories that are developing
the new techniques. They will have an even more important role in
establishing an accurate diagnosis for those infants who have NBS-
positive results and in ensuring that these children are given the best
possible and most appropriate treatment.
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